FDA says reviewing risks of Glaxo diabetes drug

(Reuters) - "FDA has not confirmed the clinical significance of the reported increased risk in the context of other studies," Meyer told reporters during a conference call.




"Further, the FDA does not know whether the other approved treatments in the same class of drugs ... have less, the same, or other greater such risks," he said.


Read more at Reuters.com Business News